FLAGYL 375 Rx

Select the drug indication to add to your list

FLAGYL 375

Bacterial infections
Protozoal infections
Vaginal infections
Only 4 drugs may be compared at once

Generic Name and Formulations:

Metronidazole 375mg; caps.

Company:

Pfizer Inc.

Select therapeutic use:

Indications for FLAGYL 375:

Susceptible anaerobic infections, including intraabdominal, skin and skin structures, gynecologic, bacterial septicemia, bone and joint, CNS, lower respiratory tract, endocarditis.

Adult:

7.5mg/kg every 6hrs for 7–10 days; max 4g/24hrs. Serious infections: parenteral form usually used first. Bone/joint, lower respiratory tract, endocardium infections: may need to treat longer. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.

Children:

Not established.

Contraindications:

Pregnancy (1st trimester for trichomoniasis). Within 2 weeks of disulfiram (possible psychotic reactions). Concomitant alcohol during or at least 3 days after treatment.

Warnings/Precautions:

Discontinue if abnormal neurological symptoms occur. Candidiasis. History of blood dyscrasias. Monitor for leukopenia; do CBCs before, during and after therapy. IV: risk of severe/fatal hepatotoxicity in Cockayne Syndrome; obtain LFTs (at baseline, within first 2–3 days after starting, frequently during therapy, and after completion); discontinue if elevated. Hepatic or renal impairment; monitor. Elderly: monitor serum levels. Pregnancy (Cat.B). Nursing mothers: not recommended.

See Also:

FLAGYL

Metronidazole Injection

Pharmacological Class:

Nitroimidazole.

Interactions:

See Contraindications. May potentiate oral anticoagulants, lithium; monitor. Avoid concomitant busulfan; if needed, adjust busulfan dose and monitor. May be antagonized by phenobarbital, phenytoin, other hepatic enzyme inducers. May impair phenytoin clearance. May be potentiated by cimetidine, other hepatic enzyme inhibitors. IV: may potentiate 5-FU, vecuronium, CYP3A4 substrates (eg, amiodarone, tacrolimus, cyclosporine,carbamazepine, phenytoin, quinidine); monitor. May interfere with serum chemistry tests.

Adverse Reactions:

Nausea, headache, anorexia, vomiting, metallic taste, dysuria, cystitis; seizures, encephalopathy, optic/peripheral neuropathy, aseptic meningitis.

How Supplied:

Tabs—50, 100; Caps 375mg—50; IV—contact supplier

Indications for FLAGYL 375:

Amebic dysentery. Amebic liver abscess.

Adult:

Give 3 times daily for 5–10 days. Dysentery: 750mg. Abscess: 500mg or 750mg. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.

Children:

35–50mg/kg/24hrs in 3 divided doses for 10 days. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.

Contraindications:

Pregnancy (1st trimester for trichomoniasis). Within 2 weeks of disulfiram (possible psychotic reactions). Concomitant alcohol during or at least 3 days after treatment.

Warnings/Precautions:

Discontinue if abnormal neurological symptoms occur. Candidiasis. History of blood dyscrasias. Monitor for leukopenia; do CBCs before, during and after therapy. IV: risk of severe/fatal hepatotoxicity in Cockayne Syndrome; obtain LFTs (at baseline, within first 2–3 days after starting, frequently during therapy, and after completion); discontinue if elevated. Hepatic or renal impairment; monitor. Elderly: monitor serum levels. Pregnancy (Cat.B). Nursing mothers: not recommended.

See Also:

FLAGYL

Pharmacological Class:

Nitroimidazole.

Interactions:

See Contraindications. May potentiate oral anticoagulants, lithium; monitor. Avoid concomitant busulfan; if needed, adjust busulfan dose and monitor. May be antagonized by phenobarbital, phenytoin, other hepatic enzyme inducers. May impair phenytoin clearance. May be potentiated by cimetidine, other hepatic enzyme inhibitors. IV: may potentiate 5-FU, vecuronium, CYP3A4 substrates (eg, amiodarone, tacrolimus, cyclosporine,carbamazepine, phenytoin, quinidine); monitor. May interfere with serum chemistry tests.

Adverse Reactions:

Nausea, headache, anorexia, vomiting, metallic taste, dysuria, cystitis; seizures, encephalopathy, optic/peripheral neuropathy, aseptic meningitis.

How Supplied:

Tabs—50, 100; Caps 375mg—50

Indications for FLAGYL 375:

Trichomoniasis.

Adult:

375mg twice daily for 7 days. Before repeating course, reconfirm diagnosis and allow 4–6 wks between courses. Treat consorts also. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.

Children:

Not established.

Contraindications:

Pregnancy (1st trimester for trichomoniasis). Within 2 weeks of disulfiram (possible psychotic reactions). Concomitant alcohol during or at least 3 days after treatment.

Warnings/Precautions:

Discontinue if abnormal neurological symptoms occur. Candidiasis. History of blood dyscrasias. Monitor for leukopenia; do CBCs before, during and after therapy. IV: risk of severe/fatal hepatotoxicity in Cockayne Syndrome; obtain LFTs (at baseline, within first 2–3 days after starting, frequently during therapy, and after completion); discontinue if elevated. Hepatic or renal impairment; monitor. Elderly: monitor serum levels. Pregnancy (Cat.B). Nursing mothers: not recommended.

See Also:

FLAGYL

FLAGYL ER

Pharmacological Class:

Antiprotozoal/antibacterial.

Interactions:

See Contraindications. May potentiate oral anticoagulants, lithium; monitor. Avoid concomitant busulfan; if needed, adjust busulfan dose and monitor. May be antagonized by phenobarbital, phenytoin, other hepatic enzyme inducers. May impair phenytoin clearance. May be potentiated by cimetidine, other hepatic enzyme inhibitors. IV: may potentiate 5-FU, vecuronium, CYP3A4 substrates (eg, amiodarone, tacrolimus, cyclosporine,carbamazepine, phenytoin, quinidine); monitor. May interfere with serum chemistry tests.

Adverse Reactions:

Nausea, headache, anorexia, vomiting, metallic taste, dysuria, cystitis; seizures, encephalopathy, optic/peripheral neuropathy, aseptic meningitis.

How Supplied:

Tabs—50, 100; ER—30; Caps 375mg—50